MD Quote, Financials, Valuation and Earnings

Kindly MD, Inc. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of -22162.75%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat Kindly MD, Inc.'s return on equity of -91.57%.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 1.69%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 126.86%. Given that Kindly MD, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe Kindly MD, Inc. is more attractive than Pediatrix Medical Group, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.766, which suggesting that the stock is 23.447% less volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. Pediatrix Medical Group, Inc.'s net income of $71.7M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.77x while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 15.44x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SRx Health Solutions, Inc. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of -13.47%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat SRx Health Solutions, Inc.'s return on equity of --.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 1.69%. On the other hand SRx Health Solutions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pediatrix Medical Group, Inc. has higher upside potential than SRx Health Solutions, Inc., analysts believe Pediatrix Medical Group, Inc. is more attractive than SRx Health Solutions, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.766, which suggesting that the stock is 23.447% less volatile than S&P 500. In comparison SRx Health Solutions, Inc. has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.069%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SRx Health Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. SRx Health Solutions, Inc. pays out -- of its earnings as a dividend.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are larger than SRx Health Solutions, Inc. quarterly revenues of $7.2M. Pediatrix Medical Group, Inc.'s net income of $71.7M is higher than SRx Health Solutions, Inc.'s net income of -$964K. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.77x while SRx Health Solutions, Inc.'s PE ratio is 0.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 0.07x for SRx Health Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of -10.08%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 1.69%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 101.24%. Given that The Oncology Institute, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Pediatrix Medical Group, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.766, which suggesting that the stock is 23.447% less volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.817%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are larger than The Oncology Institute, Inc. quarterly revenues of $136.6M. Pediatrix Medical Group, Inc.'s net income of $71.7M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.77x while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 0.60x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of 9.98%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat U.S. Physical Therapy, Inc.'s return on equity of 8.6%.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 1.69%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $105.17 which suggests that it could grow by 38.05%. Given that U.S. Physical Therapy, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe U.S. Physical Therapy, Inc. is more attractive than Pediatrix Medical Group, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.766, which suggesting that the stock is 23.447% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.320, suggesting its more volatile than the S&P 500 by 32.001%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. U.S. Physical Therapy, Inc. offers a yield of 2.36% to investors and pays a quarterly dividend of $0.45 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 95.62% of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are larger than U.S. Physical Therapy, Inc. quarterly revenues of $197.1M. Pediatrix Medical Group, Inc.'s net income of $71.7M is higher than U.S. Physical Therapy, Inc.'s net income of $19.7M. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.77x while U.S. Physical Therapy, Inc.'s PE ratio is 32.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 1.52x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.